Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553), a pharmaceutical company based in China, has announced the withdrawal of its market filing for a generic version of Cytosar (cytarabine), a drug originally developed by US firm Viatris. The decision to withdraw the filing, which was initially submitted in September 2022, is in line with the company’s research and development strategy, as per the stock exchange announcement.
Cytarabine is an antimetabolite drug primarily used for inducing remission and maintenance therapy in cases of acute non-lymphocytic leukemia in both adults and children. In China, Sinopharma was the first to pass the generic quality consistency evaluation (GQCE) for its generic version of the drug in December 2022.- Flcube.com
